Background: High-dose therapy and autologous stem-cell transplant (HDT/ASCT) is the preferred treatment of chemosensitive relapsed/refractory Hodgkin lymphoma (HL). The role for HDT/ASCT in chemoresistant HL is less well defined. We evaluated long-term outcomes of relapsed/refractory HL patients whose disease was refractory to secondary chemotherapy preceding HDT/ASCT.
introduction
Over 80% of patients with advanced Hodgkin lymphoma (HL) enter a complete remission after primary therapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) or ABVD-like treatment; however, up to 40% of patients eventually relapse and require additional therapy [1, 2] . In addition, despite excellent outcomes for patients with limited stage or favorable HL, 10%-15% relapse after primary therapy [3, 4] . Based on two randomized phase III trials, high-dose therapy and autologous stem-cell transplantation (HDT/ASCT) is the preferred treatment of relapsed and refractory HL patients with chemosensitivity to secondary (salvage) therapy, with cure rates approximating 40%-50% [5, 6] . These findings have been confirmed in a number of large single-center and registry studies, with consistent long-term progression-free survival (PFS) of more than 60% for patients with relapsed HL and more than 30% for those who are refractory to their initial therapy [7] [8] [9] [10] . The role for HDT/ASCT in disease that is chemoresistant to secondary therapy is less well defined and many centers do not offer this treatment to such patients [9, [11] [12] [13] .
Numerous studies have identified prognostic factors at time of HDT/ASCT that predict for poor outcome. One of the most consistently identified adverse prognostic factor reported is duration of response to primary therapy, with patients with refractory HL reported to have significantly worse outcomes after transplant compared with patients in first relapse (REL1) [8, 9, 13, 14] . Chemoresistance to secondary therapy before HDT/ASCT has also been reliably identified as an adverse prognostic marker [7-9, 13, 15] . Hazard ratios for effect on OS and PFS have been reported as high as 5.3 [95% confidence interval (CI) 3.1-9.1] and 2.9 (95% CI 1.7-5.0), respectively [9] ; however, it remains unclear whether the worse outcomes seen in this high-risk group are sufficiently poor to justify withholding this potentially curative therapy. In the current era, there are several secondary regimens for relapsed or refractory HL commonly employed including DHAP (cisplatin, cytarabine, and dexamethasone), ICE (ifosfamide, carboplatin, and etoposide), and GDP (gemcitabine, dexamethasone, and cisplatin) [16] [17] [18] . No single regimen has demonstrated superiority over another and choice is generally based on toxicity profile. Response rates to these regimens range from 66% to 89% [16] [17] [18] , meaning that 10%-30% of refractory and relapsed HL patients do not respond and therefore may not be considered for HDT/ASCT. Survival outcomes for such patients are very poor, with a median of 3 months reported in one series [11] . Since 1985, HDT/ASCT has been recommended in the province of British Columbia (BC), Canada, for all HL patients with progressive disease despite primary ABVD-type therapy, irrespective of response to secondary therapy. All eligible patients in the province, population 4.5 million [19] , are referred for consideration of HDT/ASCT to a single tertiary care center, the Leukemia/Bone Marrow Transplant (BMT) Program of BC. Patients are uniformly treated according to era-specific provincial guidelines. The primary objective of this population-based analysis was to evaluate the long-term outcomes of relapsed or refractory HL patients whose disease was refractory to secondary chemotherapy preceding HDT/ASCT, in order to determine whether HDT/ASCT should be offered to such patients.
patients and methods patient selection
We reviewed all HL patients who underwent HDT/ASCT for primary progression (PP) or REL1 after initial treatment with chemotherapy with or without radiation therapy (RT) in BC from March 1985 to end of December 2011. All patients were uniformly treated through the Leukemia/BMT Program of BC according to era-specific guidelines. There were no age cutoffs; however, those transplanted under pediatric protocols at BC Children's Hospital or outside the province were excluded. Diagnostic biopsies were centrally reviewed by a BC Cancer Agency (BCCA) hematopathologist and clinical staging and primary treatment regimens were based on BCCA protocols at the time of HL diagnosis (www.bccancer.bc.ca). Progressive disease or relapsed HL was determined by clinical and radiological parameters, with pathologic confirmation where possible. Secondary therapy was variable based on initial therapy, pattern of relapse, and available protocols at the time of relapse. Regardless of response to secondary therapy, all patients with PP or REL1 were enrolled on HDT/ASCT protocols approved by the Institutional Review Boards of the BCCA, Vancouver General Hospital, and the University of BC. All patients provided written informed consent for HDT/ASCT. Clinical and follow-up data were obtained from the prospectively maintained Leukemia/BMT Program of BC and BCCA Lymphoid Cancer Databases and was supplemented with retrospective data collection from hospital, clinical, and individual physicians' records. This study was approved by the BCCA and University of BC clinical research ethics boards.
high-dose therapy and autologous stem-cell transplant
See supplementary material, available at Annals of Oncology online for details regarding HDT/ASCT eligibility criteria and harvesting procedures. Conditioning regimens varied according to time period and included cyclophosphamide, carmustine, and etoposide (CBV) from 1985 to 1988, and CBV with a reduced dose of carmustine plus cisplatin (CBVP) from 1988 onward, as previously described [20] . Due to concern for pulmonary toxicity in certain patients, carmustine, etoposide, cytarabine, and melphalan (BEAM) conditioning was introduced as per BMT physician discretion beginning 2005 at standard doses [6] . Consolidative RT was administered between 1 and 3 months post-HDT/ASCT at physician discretion. Supportive care was standardized but varied over time according to institutional policy [20] [21] [22] .
statistical analysis
The primary and secondary outcomes were overall survival (OS) and failurefree survival (FFS), respectively. OS was calculated from date of HDT/ASCT to date of death from any cause; living patients were censored on the last date the patient was known to be alive. FFS was calculated from date of HDT/ASCT to date of HL relapse, transplant-related mortality (TRM), or death due to HL; patients alive without progression or those who died from causes unrelated to HL or acute toxicity from HL treatment or HDT/ASCT were censored on date of last follow-up or death, respectively. Survival estimates were calculated using the Kaplan-Meier method and compared using the log-rank test. Cause of death was classified as progressive HL, TRM, secondary malignancy, or other.
response criteria and progression categories
Patients were considered to have chemosensitive (S) disease if they had clinical and/or radiographic response ≥50% in all sites of disease to chemotherapy preceding HDT/ASCT; chemoresistant (R) disease if they had stable disease (<50% reduction in all sites) or progression during chemotherapy preceding HDT/ASCT; or untested/unknown (U) disease if no secondary therapy was administered or response was not evaluated. PP was defined as progression during or within 3 months of completion of initial therapy and relapsed disease (REL1) was defined as progression more than 3 months after completion of initial therapy.
To evaluate the impact of chemoresistance on outcomes, patients were grouped into six categories based on whether they had PP or REL1 disease, and whether they were R, S, or U to secondary therapy. Univariate and multivariate Cox regression analyses were carried out to assess the effect of responsiveness to secondary therapy, as well as other covariates, on OS and FFS (details in supplementary material, available at Annals of Oncology online only). For all statistical tests, significance was defined at a two-tailed significance level of 0.05. The statistical programming language used was STATA version 12.0.
results Two hundred fifty-six patients underwent HDT/ASCT for REL1 (n = 166, 65%) or PP (n = 90, 35%) HL from January 1985 to December 2011 in BC. Baseline and transplant characteristics of the entire cohort are shown in Table 1 . TRM was 6% (n = 15). Thirteen of 15 deaths due to TRM occurred before the year 2000, with no deaths due to TRM since 2005.
For the entire cohort, 10-year OS was 62% (median 21.7 years) and 10-year FFS was 57% (median not reached), shown in Figure 1A and B. Patients with PP disease had a significantly worse OS and FFS compared with those in REL1 (10-year OS 43% versus 72%, respectively, P < 0.001; 10-year FFS 40% versus 67%, respectively, P < 0.001), Figure 1C and D. Survival outcomes were analyzed by response to secondary chemotherapy in both the PP and REL1 groups. Although patients whose disease was resistant to secondary chemotherapy did worse than those with chemosensitive or untested disease, OS and FFS remained greater than 25% with long-term follow-up in all groups (supplementary Table S1 , available at Annals of Oncology online only, and Figure 2 ). There was no statistically significant difference in FFS between those whose disease was sensitive to secondary therapy compared with those who were chemoresistant in both the PP (10-year FFS 46.8% versus 31.3%, respectively, P = 0.09) and REL1 (10-year FFS 64% versus 51.4%, respectively, P = 0.08) groups. There was a statistically significant difference in OS in the PP group between those whose disease was sensitive versus resistant to secondary therapy (10-year OS 52% versus 28.6%, P = 0.04) but not in the REL1 group (10-year OS 71.2% versus 59.4%, respectively, P = 0.27). Among patients whose disease was resistant to secondary chemotherapy, there was no statistical difference in FFS when those with progressive disease (PD) versus stable disease (SD) were compared (10-year FFS 27% versus 46%, respectively, P = 0.08).
Univariate analysis of factors affecting OS and FFS was carried out (supplementary Table S2 , available at Annals of Oncology online only). Those with PP disease had significantly worse OS than those in REL1 (HR 2.27, 95% CI 1.52-3.38, P < 0.001) and FFS (HR 2.34, 95% CI 1.59-3.43, P < 0.001). To analyze the effect of response to secondary chemotherapy on survival outcomes, those who were untested or unknown response (U) were omitted, leaving 176 patients available for analysis. Chemoresistance was associated with an inferior OS (HR 1.97, 95% CI 1.18-3.32, P = 0.01) and FFS (HR 2.07, 95% CI 1.28-3.34, P = 0.003). No other covariates were found to significantly affect OS or FFS. Multivariate analysis is shown in supplementary Table S3 , available at Annals of Oncology online. After controlling for covariates, resistance to secondary chemotherapy predicted for post-transplant mortality (HR 1.80, 95% CI 1.04-3.11, P = 0.037) and FFS (HR 1.74, 95% CI 1.06-2.86, P = 0.029). When the PP and REL1 groups were analyzed separately, there remained a significant effect of resistance to secondary therapy on OS in the PP group after controlling for covariates (HR 2.54, 95% CI 1.05-6.13, P = 0.039), but not in the REL1 group (P = 0.162). There was no significant effect of resistance to secondary therapy on FFS in either the PP group (P = 0.06) or REL1 group (P = 0.113).
For the 93 patients who relapsed after HDT/ASCT, median time to relapse was 7.4 months (range, 0.9-91 months). Median OS was 2.6 years (95% CI 0.5-5.6) shown in supplementary Figure S1 , available at Annals of Oncology online, with 17 of 93 (18%) patients living longer than 5 years after HDT/ASCT. Of those 17 patients, 7 had limited stage relapse treated with RT 
discussion
In this large uniformly treated cohort of HL patients with longterm follow-up, chemoresistance preceding HDT/ASCT was identified as a poor prognostic factor, particularly for PP patients; however, this poor prognostic factor could be partially overcome by HDT/ASCT, resulting in cure in >30% of patients across all chemoresistant groups. Our results are consistent with previous single-centre and registry studies which demonstrate that resistance to secondary chemotherapy before HDT/ASCT predicts for worse outcomes [7] [8] [9] . Given these findings, patients with chemoresistant disease are often subjected to additional cytoreductive therapy in an attempt to obtain a response before HDT/ASCT. For example in a report of 30 relapsed or refractory HL patients who received a second salvage regimen with vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine after failure of first-line salvage therapy, responses were seen in 21 patients (70%). All 21 patients demonstrating a response went on to transplant (20 BEAM-autotransplant and 1 allotransplant) and had a median OS of 38 months, compared with 16 months for those who were not transplanted (P < 0.001) [23] . Villa et al. reported that 24% of relapsed/refractory HL patients did not respond to an initial secondary platinum-containing therapy [11] . Of 19 patients who went on to receive second salvage therapy with mini-BEAM, 10 (53%) did not achieve at least a partial response (PR) and therefore HDT/ASCT was withheld. All 10 patients died of progressive HL, with a median OS of 3 months after mini-BEAM [11] . These reports demonstrate that even with additional more intensive cytoreductive therapy, 30%-40% of patients will remain chemoresistant and have poor outcomes if no further dose-intensive therapies are administered.
Although our data demonstrate that patients who are resistant to secondary therapy have a trend toward worse outcomes, they may still be cured in up to 30% in the primary progressive setting and up to 50% after REL1. Interestingly, in the REL1 group, the 10-year FFS of 51.4% and 10-year OS of 59.4% were not significantly different than the FFS (64%) and OS (71.2%) of REL1 patients with chemosensitive disease (P = 0.08 and P = 0.11, respectively). This effect persisted in multivariate analysis after adjustment for covariates. Therefore, HL patients who relapse more than 3 months after completion of primary therapy may reasonably be taken to HDT/ASCT irrespective of response to secondary therapy. For those with refractory disease who progressed during or within 3 months of completion of primary therapy, resistance to secondary therapy did significantly predict for worse OS (28.6% versus 52%, P = 0.04) but not FFS (31.3% versus 46.8%, P = 0.09). Again, these findings persisted in multivariate analysis. These patients may therefore be considered for alternate strategies to optimize HDT/ASCT such as the addition of novel agents like brentuximab vedotin to pretransplant conditioning, post-transplant maintenance or consolidation therapy. These strategies are being evaluated in ongoing clinical trials.
Although the TRM reported in this study was slightly higher than that seen in more recent cohorts of HL patients undergoing HDT/ASCT [9] , 13 of 15 deaths due to TRM occurred before 2000, and there have been no deaths due to TRM since 2005. This likely reflects advances in hematopoietic stem-cell transplantation and supportive care, as well as more careful selection of patients, conditioning regimens, and reservation of RT until after the transplant to prevent pulmonary toxicity, which was the greatest cause of TRM in our series.
Our study has several limitations. This is a retrospective study and therefore examined only reliable end points including OS and FFS. Patient selection and treatments varied by time period; however, this was consistent across patients since all patients were treated under the same provincial protocols. Although our provincial policy is to transplant all relapsed/refractory HL, regardless of response to secondary therapy, it is possible that some treating physicians elected not to refer for HDT/ASCT due to disease progression; if this were the case, the outcome for the chemoresistant patients may be overestimated. This is a population-based study with data obtained outside of a clinical trial setting; therefore, not all data were complete. In particular, response assessment to secondary therapy was determined by both clinical and radiographic response and was not subject to the same rigorous response assessment as in clinical trials. Functional imaging, which has been shown to be prognostic in this setting [24] , was not employed routinely to assess response to secondary chemotherapy in our study. It is recognized that 68% of patients in the chemoresistant group had stable disease and may have been in fact in a metabolic complete response; however, we also observed that when those with true progressive disease were analyzed separately, there was no significant difference in cure rates. Numbers for the comparison of PD versus SD patients are small though and therefore must be interpreted with caution.
In conclusion, these data suggest that all patients with relapsed or refractory HL should be considered for HDT/ASCT, even if they do not respond to secondary therapy. We have demonstrated that even patients who were doubly resistant to both primary and secondary therapy were cured in 31% of cases. In particular, patients who relapsed more than 3 months after completion of primary therapy had long-term FFS of 51%, which was not significantly different from those with chemosensitive disease. HDT/ASCT should therefore be considered in all transplant eligible patients, regardless of responsiveness to secondary chemotherapy. 
